Literature DB >> 6283982

Cytomegalovirus immune plasma in bone marrow transplant recipients.

D J Winston, R B Pollard, W G Ho, J G Gallagher, L E Rasmussen, S N Huang, C H Lin, T G Gossett, T C Merigan, R P Gale.   

Abstract

The effects of passive immunization on cytomegalovirus infection and interstitial pneumonia in marrow transplants were evaluated in a randomized, controlled trial. Twenty-four patients received cytomegalovirus immune plasma before and after transplantation, and 24 patients were controls. Although the incidence of cytomegalovirus infection was similar in the control and plasma groups, symptomatic infection (12 of 24 versus five of 24, p = 0.07) and interstitial pneumonia (11 of 24 versus five of 24, p = 0.12) occurred less frequently in the group receiving plasma. Cytomegalovirus infection occurred in 11 of 13 recipients of leukocyte transfusions and in 16 of 35 patients not given leukocyte transfusions (p = 0.02). Among patients not given leukocyte transfusions, the incidence of cytomegalovirus infection was similar in the control and plasma groups, but symptomatic infection (eight of 18 versus one of 17, p = 0.03) and interstitial pneumonia (nine of 18 versus one of 17, p = 0.01) were significantly less in the group receiving plasma. These results suggest that passive immunization modifies cytomegalovirus infection in humans and prevents interstitial pneumonia in marrow transplants especially when leukocyte transfusions are not used.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6283982     DOI: 10.7326/0003-4819-97-1-11

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  25 in total

Review 1.  Prevention of viral infections after bone marrow transplantation.

Authors:  U Schuler; G Ehninger
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

2.  Evaluation of four methods for cytomegalovirus antibody detection for use by a bone marrow transplantation service.

Authors:  D S Leland; K A Barth; E B Cunningham; J Jansen; G J Tricot; M L French
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

Review 3.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

4.  Cytomegalovirus infection complicating immunosuppressive treatment.

Authors:  P D Griffiths
Journal:  Postgrad Med J       Date:  1988-01       Impact factor: 2.401

5.  Evaluation of immunoglobulin G preparations for anti-cytomegalovirus antibodies with reference to neutralizing antibody in the presence of complement.

Authors:  Y Eizuru; I Ueno; Y Minamishima
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

6.  Cytomegalovirus (CMV) infections in patients receiving CMV-IgG-hyperimmunoglobulin prophylaxis after bone-marrow transplantation.

Authors:  T Schmeiser; W Heit; R Arnold; D Bunjes; M Wiesneth; B Hertenstein; W Hampl; H Heimpel
Journal:  Klin Wochenschr       Date:  1987-10-15

7.  Influence of immunosuppressive therapy with azathioprine and prednisolone on serum-immunoglobulin concentration in renal transplanted patients.

Authors:  R H Dennin; E Schulz; K Sack; K Dalhoff; J Hoyer
Journal:  Klin Wochenschr       Date:  1985-11-04

Review 8.  Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.

Authors:  M F Siadak; K Kopecky; K M Sullivan
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam Heart Transplant Program experience.

Authors:  A H Balk; W Weimar; P H Rothbarth; K Meeter; H J Metselaar; B Mochtar; M L Simoons
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

10.  Viral polypeptides detected by a complement-dependent neutralizing murine monoclonal antibody to human cytomegalovirus.

Authors:  L Rasmussen; J Mullenax; R Nelson; T C Merigan
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.